biosimilar, FDA and insulin
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus.
Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...
This human insulin analogue that comes in disposable pens prefilled with 1, 1.5, or 3 mL, dosed in 10-unit increments1 binds reversibly to albumin, which extends its half-life to around 7 days.
Today, Plantsulin blends this century-old discovery with modern scientific validation to offer a fast, convenient “whole-body reboot” for maintaining optimal glucose levels. Unlike restrictive diets ...
News Medical on MSN15d
Revolutionizing diabetes care with innovative targets and therapeutic optionsA thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and ...
Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback